Radiosurgery for Type II NeurofibromatosisRowe J. · Radatz M. · Kemeny A.
National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
A summary of our radiosurgical experience treating type II neurofibromatosis (NF2) vestibular schwannomas (VSs), based on a retrospective consecutive series of 122 tumours in 92 patients, with an extended series of a further 22 patients (906 patient-years of follow-up) to investigate the risk of malignancy after radiosurgery. With current techniques, we estimate that 8 years after radiosurgery for NF2 VS, 20% of patients will have required further treatment, 50% will be well controlled, and in 30% there will have been some concern about control, but they will have been managed conservatively. Three years after treatment, approximately 40% retain their functional hearing, 40% have some deterioration, 20% becoming deaf in that ear. The risk of facial palsy was 5%. Two malignancies were recorded after radiosurgery, in one the malignant behaviour preceded treatment. This is less than the previously reported rate of spontaneously developing malignant gliomas in NF2. Whilst the clinical results are far worse than those achieved treating sporadic tumours, this applies equally to the results of surgery or observation when treating NF2 tumours. It is important therefore that these patients are given advice specific for NF2. Considering this, we believe that radiosurgery remains a valuable minimally invasive treatment option for selected NF2 patients.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.